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Abstract
Background: The Activin A and bone morphogenetic protein (BMP) pathways are critical regulators of the immune
system and of bone formation. Inappropriate activation of these pathways, as in conditions of congenital heterotopic
ossification, are thought to activate an osteogenic program in endothelial cells. However, if and how this occurs in
human endothelial cells remains unclear.
Methods: We used a new directed differentiation protocol to create human induced pluripotent stem cell (hiPSC)-
derived endothelial cells (iECs) from patients with fibrodysplasia ossificans progressiva (FOP), a congenital disease of
heterotopic ossification caused by an activating R206H mutation in the Activin A type I receptor (ACVR1). This strategy
allowed the direct assay of the cell-autonomous effects of ACVR1 R206H in the endogenous locus without the use of
transgenic expression. These cells were challenged with BMP or Activin A ligand, and tested for their ability to activate
osteogenesis, extracellular matrix production, and differential downstream signaling in the BMP/Activin A pathways.
Results: We found that FOP iECs could form in conditions with low or absent BMP4. These conditions are not normally
permissive in control cells. FOP iECs cultured in mineralization media showed increased alkaline phosphatase staining,
suggesting formation of immature osteoblasts, but failed to show mature osteoblastic features. However, FOP iECs
expressed more fibroblastic genes and Collagen 1/2 compared to control iECs, suggesting a mechanism for the tissue
fibrosis seen in early heterotopic lesions. Finally, FOP iECs showed increased SMAD1/5/8 signaling upon BMP4
stimulation. Contrary to FOP hiPSCs, FOP iECs did not show a significant increase in SMAD1/5/8 phosphorylation upon
Activin A stimulation, suggesting that the ACVR1 R206H mutation has a cell type-specific effect. In addition, we found
that the expression of ACVR1 and type II receptors were different in hiPSCs and iECs, which could explain the cell type-
specific SMAD signaling.
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Conclusions: Our results suggest that the ACVR1 R206H mutation may not directly increase the formation of
mature chondrogenic or osteogenic cells by FOP iECs. Our results also show that BMP can induce endothelial cell
dysfunction, increase expression of fibrogenic matrix proteins, and cause differential downstream signaling of the
ACVR1 R206H mutation. This iPSC model provides new insight into how human endothelial cells may contribute
to the pathogenesis of heterotopic ossification.
Keywords: ACVR1, Fibrodysplasia ossificans progressiva, Tissue fibrosis, hiPS-derived endothelial cells, BMP,
Activin A signaling
Background
Diseases of heterotopic ossification, where bone forms at
an abnormal site, provide valuable opportunities to exam-
ine the mechanisms that regulate osteogenesis. The bone
growth can range from small incidental nodules to cata-
strophic paralysis. Heterotopic ossification is found in a
wide variety of diseases, including traumatic injury, severe
burns, brain injury, and invasive surgeries [1–3]. However,
the diversity of triggers poses a significant challenge for
dissecting the cellular and molecular mechanisms that
cause heterotopic ossification. Thus, genetic conditions of
abnormal bone formation provide a valuable model for
identifying the key pathways and regulators of heterotopic
ossification in soft tissues.
Fibrodysplasia ossificans progressiva (FOP) is a congeni-
tal disease characterized by a large amount of heterotopic
ossification in postnatal muscles and tendons [4, 5] and
has been used as a prototypical model for studying hetero-
topic ossification. Most patients have a conserved muta-
tion in the Activin A type 1 (ACVR1/ALK2) gene [6–8], a
bone morphogenetic protein (BMP) receptor. BMPs are
major regulators of bone formation. They were initially
identified based on their ability to induce bone formation
in soft tissues such as muscle and tendon. The majority of
ACVR1 mutations in FOP are localized to a single amino
acid change (R206H) that is thought to increase ACVR1
signaling activity.
Histologically, the initial fibrocellular infiltrate at a bone
formation site is fibrotic and contains inflammatory cells
and endothelial cells (ECs) [7]. ECs overexpressing ACVR1
R206H may contribute to heterotopic ossification [9],
possibly via abnormal BMP signaling, by undergoing
endothelial-to-mesenchymal transition (EndMT) [10]. How-
ever, it is unclear if human FOP ECs can transdifferentiate
into osteogenic cells and directly contribute to bone
formation, if another mechanism leads to the increase in
ECs in FOP lesions [7, 9], if ECs are crucial in the very
early steps of heterotopic ossification, or if human FOP
ECs also respond abnormally to BMP or Activin A signals
acting on the ACVR1 R206H receptor [11, 12].
Studies on human skeletal development are hampered
by a number of factors, including the rare access to fetal
material of developing bones, the difficulty of obtaining
primary cells for detailed laboratory analysis, the ubiqui-
tous nature of many of the ligands, and the technical
and ethical problems surrounding the potential human
genetic experiments needed to test pathways and hy-
potheses. Given that primary tissues cannot be obtained
from patients with FOP because of heterotopic ossifica-
tion at the surgical site, patient-derived human induced
pluripotent stem cells (hiPSCs) [13] provide a strategy to
create FOP cells for study in vitro [14].
The recent development of hiPSCs has made genetic
diseases easier to study. hiPSCs can be derived directly
from patients with existing genetic mutations and can
form any cell in the body. hiPSCs also allow us to study
the effect of single mutations in the endogenous locus
and in a cell-autonomous fashion without the inherent
complications of transgenic or overexpression studies.
Thus, iPSC-derived tissues can model early developmen-
tal events and provide diseased human tissues that can-
not be obtained from a patient.
Here, we use hiPSCs from patients with FOP [14] as a
model of cell-autonomous signaling induced by the
ACVR1 R206H mutation to test if the mutation increases
the formation of potential osteoprogenitors in the EC
lineage, and if hiPSC-derived endothelial cells (iECs) ex-
pressing ACVR1 R206H show increased plasticity towards
osteogenesis. We also investigate the cellular mechanisms
by which ECs may contribute to heterotopic ossification.
Methods
Cell culture and differentiation
Pluripotent hiPSC lines derived from control (wild type,
WT) and FOP fibroblasts previously described [14, 15]
were maintained in mTeSR1 medium (StemCell Technolo-
gies) on irradiated SNL (mouse fibroblast STO cell line
transformed with neomycin resistance and murine LIF
genes) feeder cells [16]. SNLs were removed by at least one
passage in feeder-free conditions on growth-factor-reduced
Matrigel (Corning)-coated plates (150–300 μg/ml, 40 min
coating) before use in differentiation assays. ROCK inhibi-
tor Y-27632 (10 μM, StemCell Technologies) dissolved in
100 % DMSO was added to mTeSR1 at the time of passa-
ging and removed the following day.
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hiPSC lines were differentiated into iECs according to
protocols previously described [17]. Embryoid bodies
(EBs) were formed from hiPSCs and cultured in aggrega-
tion medium Stem-Pro-34 (Invitrogen) supplemented
with 2 mM glutamine, 150 mg/ml transferrin, 1 mM
ascorbic acid, and 0.4 μM monothioglycerol (Sigma-
Aldrich). EBs were cultured in aggregation medium with
5 ng/ml human basic fibroblast growth factor (bFGF),
3.6 ng/ml Activin A, and 12 ng/ml BMP4 (Peprotech).
On day 6 of differentiation, cells were sorted for endothe-
lial progenitor markers PECAM and KDR and plated on
fibronectin (Sigma-Aldrich) in endothelial cell medium
(ECM, ScienCell). These iECs were able to be passaged up
to three times. iEC cultures were also treated with the
Activin A inhibitor follistatin at 1 μg/ml (Peprotech).
Mineralization assay
hiPSCs maintained in feeder-free conditions were plated in
20 % mTeSR1 mixed with 80 % OB (osteoblastic
mineralization) medium [Dulbecco’s Modified Eagle’s
Medium with 20 % fetal bovine serum, 2 mM Gluta-
MAXTM, 10 mM glycerol-2-phosphate, 1 nM dexametha-
sone, 0.1 mM 2-mercaptoethanol, and 50 μg/ml L-ascorbic
acid 2-phosphate sesquimagnesium salt hydrate, 1 % non
essential amino acids] and Y-27632 (10μM) at 400,000 cells
per well in gelatin-coated 24-well plates [14]. The medium
was replaced on day 2 with 100 % OB medium. The
medium was changed every other day until day 12. Samples
for the alkaline phosphatase staining were fixed on day 15
in 95 % ethanol for 10 min to 1 h at room temperature and
incubated with substrate BCIP/NBT (Sigma-Aldrich) for
10 min at 37 °C. Staining was quantified via Image J [18].
Reverse Transcriptase-PCR and quantitative expression
analysis
Total RNA was prepared using TRI Reagent (Sigma-
Aldrich) and treated with the Turbo DNA-Free kit
(Ambion). One microgram of total RNA was reverse
transcribed into cDNA with the iScript cDNA Synthe-
sis kit (BioRad) according to manufacturer instructions.
Real-time quantitative PCR was performed in triplicate
with VeriQuest Probe qPCR Master Mix (Affymetrix) or
ABI’s Sybr Green PCR Master Mix on a ViiA 7 thermocy-
cler (Life Technologies). Some low-yield cDNA samples
were pre-amplified and analyzed using the BioMark 48.48
Dynamic Array nanofluidic chip (Fluidigm Inc., USA)
according to manufacturers’ instructions. Taqman primer
and Sybr Green probe sets are listed in Additional file 1:
Table S1 and Additional file 2: Table S2. GAPDH or β-actin
was used for normalization as an endogenous control.
Immunostaining
iECs were fixed with 4 % paraformaldehyde/phosphate-
buffered saline for 10 min at room temperature, then
blocked with 5 % bovine serum albumin. Cells were
stained overnight with primary antibodies to PECAM
(5 μg/ml, R&D Systems) and VE-Cadherin (2 μg/ml,
R&D Systems). Secondary antibodies were from Life
Technologies: Alexa488-conjugated goat anti-mouse
IgG (1:500) and Alexa555-conjugated goat anti-rabbit
IgG (1:500). Nuclei were stained with DAPI in the Pro-
Long® Gold Antifade (Life Technologies) mounting
media. Images were taken using a light microscope
(Nikon Eclipse E800 or Leica DMI 4000B).
Flow cytometry
hiPSCs cultured in mineralization medium were dissociated
into single cells with collagenase type I (Worthington) for
1 h at 37 °C and then isolated by a Ficoll gradient
(Histopaque 1191, Sigma-Aldrich). Accutase was used to
generate single-cell suspensions from EBs plated overnight
on collagen IV-coated plates or from iECs grown on
fibronectin-coated plates. Cells were stained with
PECAM1-AF488, KDR-APC, and VE-Cadherin-PerCP-
Cy5.5 antibodies for endothelial markers, with CD90-
AF488, CD73-PE, and CD105-PerCP-Cy5.5 antibodies
(all from BD Pharmingen) for mesenchymal stem cell
(MSC) markers. ICAM-1-PE antibody was used in our
TNFα induction assay. Fluorescence intensity was deter-
mined for 10,000 cells in total and percentages shown in
figures are the percentage of living cells that fall within
the gate shown.
Vascular tube formation assay
Cells were seeded at 2.5 × 105 per well on 24-well plates
pre-coated with growth factor-reduced Matrigel (Corning)
and incubated for 24 h at 37 °C. Images were taken using
a light microscope (Nikon and Leica).
ELISA
Activin A levels were measured in iEC culture supernatant
using an immunoassay solid-phase ELISA (R&D Systems).
Samples were assayed in biological triplicates.
Western blot
iECs were plated on fibronectin following sorting at a
density of 7.5 × 104 cells per well of a 6-well plate and
grown for 3 days in ECM medium (ScienCell). iECs were
serum-starved for 1 h before a 40 min treatment with ei-
ther 50 ng/ml of BMP4 or Activin A (R&D Systems). Cells
were harvested in RIPA buffer (Pierce, Thermo Scientific)
supplemented with 1X protease and a phosphatase inhibi-
tor cocktail (Roche). Whole-cell lysates were prepared in
Laemmli buffer (BioRad) and resolved in 4–20 % tris-
glycine gels (BioRad). Primary antibodies towards SMAD1/
5/8 (Santa Cruz Biotechnology), phospho-SMAD1/5/8
(Cell Signaling), SMAD2/3 (Cell Signaling), and phospho-
SMAD2/3 (Cell Signaling) were used at a dilution of
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1:1000. Anti-GAPDH antibody (Thermo Scientific) was
used at a dilution of 1:10,000. Binding was visualized
with horseradish peroxidase-conjugated antibodies
(Cell Signaling) and ECL (Enhanced ChemiLumines-
cence) substrate (Thermo Scientific). An ImageQuant
LAS 4000 (GE Healthcare) was used to image the
blots and quantifications were done using Image J
software.
TNFα activation assay
Cells were seeded at 1 × 105 per well on 6-well plates
and treated with 10 ng/ml TNFα overnight at 37 °C in
5 % CO2. Cells were then harvested and stained for
ICAM-1 and PECAM for fluorescence-activated cell
sorting (FACS) analysis as discussed below.
Transwell assay
For the transwell assay, 1 × 105 cells were added onto
each transwell inserts (8.0 μm pore, Sigma-Aldrich). The
inserts were incubated for 24 h at 37 °C in 5 % CO2 with
serum-free media, with or without 50 ng/ml VEGF in
the lower chamber. Membranes from each insert were
fixed for 20 min and stained with crystal violet for 1 h.
Statistical analysis
Because each hiPSC line was derived clonally, and thus
may display different behaviors, we treated each cell line
as an individual biological replicate and pooled our
results into control or FOP categories. All statistical
analyses were completed using GraphPad Prism soft-
ware. P values were calculated using the Student’s t test.
p values ≤ 0.05 were considered statistically significant
and are shown in the figures. Non-significant p values
are not indicated for figure clarity.
Results
WT and FOP hiPSCs can form endothelial cells with equal
efficiency in a directed differentiation protocol
Multiple signaling molecules, including BMPs [10], regulate
EC formation. Also, human umbilical vein endothelial cells
(HUVECs) overexpressing ACVR1 R206H can acquire
MSC-like phenotypes via EndMT [9]. We previously
found that FOP hiPSCs show increased mineralization
compared to control hiPSCs when cultured in mineraliz-
ing conditions [14]. To determine if the ACVR1 R206H
mutation could increase the formation of ECs during
mineralization, we examined the expression of two EC
markers, PECAM and VE-Cadherin (markers of mature
ECs), at two time points during culture (Additional file 3:
Figure S1A). PECAM and VE-Cadherin expression
showed only a trend towards increased expression in the
FOP cultures. Since this could occur from a dilution effect
from non-ECs, we used FACS to quantitate cells with
PECAM and KDR, which marks endothelial progenitors
[17], and cells co-expressing MSC markers CD90, CD73,
and CD105. We found increased PECAM+/KDR+ cells
(ECs, Additional file 3: Figure S1B) but not increased
CD90+/CDE73+/CD105+ cells (MSCs, Additional file 3:
Figure S1C), suggesting that FOP hiPSCs cultured in
mineralizing conditions increased EC lineages but not
MSC lineages [14].
We next created iECs to test if FOP heterotopic ossifi-
cation could arise from increased formation of skeletal
precursors in the EC lineage without overexpression of
ACVR1 R206H (Fig. 1a) [17]. These conditions, which
contain BMP4, produced a consistent yield of approxi-
mately 20 % phenotypic iECs (PECAM+/KDR+) from
both WT and FOP hiPSC lines (Fig. 1b). These findings
suggest that the R206H mutation does not impair or
favor iEC progenitor formation from hiPSCs in our
protocol.
WT and FOP iECs show no functional differences
To characterize our FOP iECs, we next purified the iECs
and cultured them in vitro to assess their endothelial
properties (Fig. 1a, c, d). After sorting, hiPSC-derived
PECAM+/KDR+ iECs yielded more than 95 % PECAM
+/VE-Cadherin+ proliferative cells (Fig. 1c), could be
passaged up to three times (data not shown), and
retained their endothelial phenotype (Fig. 1d). WT and
FOP iECs formed vessel-like structures when cultured
on Matrigel (Additional file 4: Figure S2A), showed
increased ICAM-1 upon TNFα activation (Additional
file 4: Figure S2B), and had similar migration properties
to VEGF in transwells (Additional file 5: Figure S3). Cells
showed equivalent mRNA levels of the endothelial
markers PECAM, vWF, KDR, and TIE2 (Fig. 2a). VE-
Cadherin expression was significantly lower in FOP
iECs, suggesting a partial loss of mature endothelial
marker expression. Conversely, CD34 mRNA, a marker
for hematopoietic stem cell progenitors or vascular
endothelial progenitors and also expressed on MSCs
[19], was significantly increased in FOP iECs (Fig. 2b).
These results indicate no significant differences in func-
tionality between WT and FOP iECs but that FOP iECs
show increased expression of an endothelial progenitor-
like marker and decreased expression of one mature
endothelial gene.
FOP iECs show increased expression of alkaline
phosphatase and Collagen 1/2
Since overexpression of R206H ACVR1 can activate
EndMT to create MSC-like cells from HUVECs [9, 20],
and vascular-associated cells such as pericytes can form
osteoblasts [21], we tested if FOP iECs could be directed
towards osteogenesis. Chondrogenic and osteogenic
gene expression profiling of purified iECs cultured in
ECM showed elevated COL1A1 and COL2A1 (Fig. 2b),
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two gees that code for extracellular matrix proteins
found in bone and cartilage. FOP iECs also expressed
higher levels of the mesenchymal marker FSP-1 gene
(Fig. 2b), consistent with a predisposition towards
EndMT. Some cultures of iECs showed increased levels
of alkaline phosphatase (ALPL) mRNA (Fig. 2b), which
was unexpected as the iECs were maintained in endo-
thelial culture conditions. Although ALPL can mark
immature osteoblasts, expression of chondrogenic and
osteogenic transcription factors ( SOX9, SP7, and RUNX2)
were unchanged in FOP iECs cultured in ECM (Add-
itional file 6: Figure S4).
We next cultured our iECs in mineralization condi-
tions to test if FOP iECs could form mineral-depositing
cells via EndMT. After 15 days of culture, ALPL staining
was increased in FOP iECs (Fig. 3a, b), again suggesting
presence of osteogenic precursors; however, neither WT
nor FOP iECs showed significant mineral deposition by
von Kossa staining (data not shown), suggesting that
mineralizing osteoblastic cells were not present. Gene
expression analysis showed no difference in osteogenic
markers except for increased COL1A1 expression in FOP
iECs (Fig. 3c). These results suggest that the ACVR1
R206H mutation may not directly increase osteogenic or
chondrogenic potential in FOP iECs, but may increase
extracellular matrix production and local tissue fibrosis.
FOP iECs show increased formation in conditions not
permissive for WT cells
Because the ACVR1 R206H mutation is thought to up-
regulate BMP pathway activity [14, 22, 23], we asked if
FOP hiPSCs could form iECs in conditions not normally
permissive for control cells. hiPSCs were cultured in
varying concentrations of BMP4 during the initial EB
formation (Fig. 1a). BMP4 removal significantly inhibited
iEC formation from control hiPSCs, but the FOP hiPSCs
still formed endothelial-like cells in those conditions
(Fig. 4a). It is important to note that our differentiation
protocol also contained Activin A. Thus, the formation
of ECs at low BMP4 concentrations could result from
Fig. 1 Differentiation of human induced pluripotent stem cell (hiPSC)-derived endothelial cells (iECs) from wild type (WT) and fibrodysplasia ossificans
progressiva (FOP) hiPSC lines. a Endothelial cell differentiation protocol adapted from White et al. [17]. WT and FOP hiPSCs were induced to form
mesodermal progenitors using BMP4, Activin A, and bFGF. Embryoid bodies (EBs) were cultured in medium supplemented with VEGF and bFGF on
day 4 and plated onto collagen IV on day 5. iEC precursors were identified by KDR/PECAM positivity. Scale bars, 200 μm (hiPSCs, EBs, and EBs at day 6)
and 1 μm (hiPS-derived endothelial cells). b Mean percentage of cells expressing both PECAM and KDR by fluorescence-activated cell sorting (FACS)
analysis on day 6 of endothelial differentiation of one WT hESC line, three WT hiPSC lines, and four FOP hiPSC lines. Error bars represent the mean ±
one standard deviation of at least three independent replicates for each of the three WT and four FOP cell lines. Mean values were not statistically
different. c FACS analysis of WT and FOP hiPSCs on day 0 and day 6 of endothelial differentiation. iECs co-expressing PECAM and KDR were sorted by
FACS on day 6 and then cultured in endothelial cell medium. Analysis of PECAM and VE-Cadherin expression by FACS of sorted iECs after one passage
is shown on the right. d WT and FOP hiPSCs were differentiated as in Fig. 1A and sorted on day 6. iECs were immunostained for endothelial markers
PECAM and VE-Cadherin. Scale bars, 100 μm
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increased sensitivity to BMP4 but also from aberrant
activation of the SMAD1/5/8 pathway by Activin A in
FOP cells [11, 12]. To test this possibility, we differenti-
ated our WT and FOP hiPSCs in the absence of Activin
A. We found no significant differences in the ability of
WT or FOP hiPSCs to form iECs in the absence of or
with the full dose (3.6 ng/ml) of Activin A (Fig. 4b).
Together, these results suggest that FOP hiPSCs can
form ECs even in conditions that are not normally
permissive for WT cells and that the difference is likely
due to BMP signaling rather than Activin A signaling.
FOP iECs show increased SMAD1/5/8 signaling
To test if the increased plasticity in FOP ECs was due to
activation of the BMP pathway, we next examined if
SMAD signaling was activated in FOP iECs. When we
initially examined SMAD signaling in FOP iECs cultured
in fully supplemented media, we found no significant
differences in SMAD1/5/8 activation when WT or FOP
iECs were stimulated with BMP4 (Additional file 7: Figure
S5A). However, after serum starvation, FOP iECs showed
significantly increased phosphorylation of SMAD1/5/8
compared to WT iECs. The addition of BMP4 signifi-
cantly increased the phosphorylation of SMAD2 and
SMAD1/5/8 in WT iECs but only SMAD1/5/8 in FOP
iECs (Fig. 4c, d). These results are consistent with the fact
that BMPs have been reported to induce expression of
EndMT markers in ECs [24] and that several other studies
have reported increased SMAD2 signaling after BMP
exposure in some cancer or transformed cells [25, 26].
Expression of SMAD6, which inhibits the phosphoryl-
ation of SMAD1/5/8 [27], and SMAD7, an inhibitor of
SMAD2 and SMAD1/5/8 phosphorylation [27], was not
significantly different between WTand FOP hiPSCs. Inter-
estingly, SMAD6 expression was significantly increased in
FOP iECs compared to WT iECs. We also noticed that
expression levels depended on cell type. Expression of
SMAD7 [27] was significantly lower in iECs compared to
hiPSCs in WT cells but not in FOP cells (Fig. 5a).
Conversely, expression of SMAD6 [27] was significantly
increased in iECs compared to hiPSCs. These findings
suggest differential regulation of SMAD pathways
dependent on cell type. In addition, SMAD2 and SMAD6
may have an unexpected autoregulatory effect on the
SMAD1/5/8 pathway in FOP iECs.
Because recent studies [11, 12] showed that the
ACVR1 R206H mutation may alter Activin A signaling
in MSCs, we investigated if FOP iECs might produce or
respond to Activin A. Although the expression of Acti-
vin A was significantly increased in iEC lines compared
to hiPSC lines, we found no significant difference in
Activin A mRNA or protein levels in culture media be-
tween WT and FOP iECs (Fig. 5b). FOP hiPSCs treated
with Activin A showed increased SMAD1/5/8 phosphor-
ylation compared to WT hiPSCs (Additional file 7:
Figure S5B). In contrast, Activin A increased SMAD2
and SMAD1/5/8 phosphorylation in both WT and FOP
iECs (Fig. 4c, d). FOP iECs treated with Activin A
showed a non-significant trend towards increased
SMAD1/5/8 phosphorylation as compared to WT iECs.
Fig. 2 Loss of endothelial lineage commitment of fibrodysplasia ossificans progressiva (FOP) human induced pluripotent stem cell-derived endothelial cells
(iECs). a Gene expression analysis of endothelial markers by quantitative PCR of wild type (WT) and FOP iECs. b Mesenchymal/fibroblastic (FSP-1, CD34),
mature chondrogenic (COL2A1), and osteogenic (COL1A1, ALPL) gene expression were statistically different by Student’s t test: * p< 0.05, ** p< 0.01. Error
bars represent the mean ± one standard deviation of at least three independent replicates for each of the three WT and four FOP iEC lines
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We found no significant differences in SMAD2 phosphor-
ylation between WT and FOP iECs treated with Activin A.
This suggests that the BMP and Activin A ligands may
differentially activate separate SMADs in FOP cells as
compared to WT cells, thus leading to increased propen-
sity for EndMT. To further elucidate if the up-regulation
of mesenchymal genes found in FOP iECs could be caused
by Activin A in the media, we treated our iEC cultures
with the Activin A inhibitor follistatin. We found no sig-
nificant differences between WT and FOP iECs treated
with follistatin (Additional file 8: Figure S6). Thus, the
up-regulation of mesenchymal gene expression in FOP
iECs is not likely to be caused by Activin A.
TGFβ1 is known to play a major role in EC EndMT
[28, 29]. Stimulating our iECs with TGFβ1 significantly
increased SMAD2 phosphorylation in both WT and FOP
iEC but did not change SMAD1/5/8 phosphorylation
(Fig. 4d). This result suggests that FOP iECs respond in
the same manner as WT iECs to TGFβ1 ligand.
ACVR1 and type II receptors are differentially expressed
in hiPSCs and iECs
Our unexpected findings of mild activation of SMAD1/5/
8 by Activin A and SMAD2 by BMP4 (Fig. 4c, d) raised
the question of whether cell type-specific expression of
the ACVR1 receptors might be occurring. Expression of
WT ACVR1 was significantly increased in WT iECs and
OB iECs compared to FOP iECs and FOP OB iECs
(Fig. 5c). We also found a significant increase in WT
ACVR1 in WT iECs and in OB iECs compared to WT
hiPSCs. However, expression of R206H ACVR1 only
showed a slight increase in iECs and the ratio of R206H to
WT ACVR1 showed no significant differences between
hiPSC, iECs, and OB iECs (Fig. 5c).
Finally, we investigated if the differences seen in SMAD
activation among different cell types might be related to
altered expression of type II receptors known to bind to
ACVR1, including ACVR2A, ACVR2B, and BMPRII [30].
Although WT and FOP cells expressed similar levels of
Fig. 3 Osteogenic capacity of fibrodysplasia ossificans progressiva (FOP) human induced pluripotent stem cell-derived endothelial cells (iECs).
a FOP iECs showed increased alkaline phosphatase (ALPL) staining at day 15. b Quantification of ALPL staining from at least three independent
replicates for each of the three wild type (WT) and four FOP iECs lines. Error bars represent the mean ± one standard deviation; ** p < 0.01 by
Student’s t test. c Osteogenic and chondrogenic gene expression analysis by quantitative PCR of WT and FOP iECs cultured in 50 % endothelial
cell medium/50 % OB medium for 15 days. COL1A1 and COL2A1 gene expression were statistically different by Student’s t test: * p < 0.05. Error
bars represent the mean ± one standard deviation of at least three independent replicates for each of the three WT and four FOP iEC lines
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ACVR2A, ACVR2B, and BMPRII (Fig. 5d), we again noted
significant differences in the absolute expression levels
between cells types. ACVR2A gene expression was
significantly lower in WT iECs and OB iECs than in
hiPSCs. ACVR2B was significantly lower only in OB iECs
compared to WT and FOP hiPSCs and iECs. Interestingly,
Fig. 4 Fibrodysplasia ossificans progressiva (FOP) human induced pluripotent stem cell (hiPSC)-derived endothelial cells (iECs) form in conditions
not permissive for controls and respond differently upon stimulation. a Wild type (WT) and FOP hiPSCs were differentiated as illustrated in Fig. 1d
using different concentration of BMP4 (0, 1, 4, and 12 ng/ml). Shown is the mean percentage of PECAM+/KDR+ cells analyzed by fluorescent-activated
cell sorting (FACS) at day 6 from three WT and four FOP hiPSC lines in at least three separate experiments for each group. Mean values were statistically
different for 0, 1, and 4 ng/ml of BMP4. b WT and FOP hiPSCs were differentiated with or without supplemental Activin A. FACS analysis of PECAM
+/KDR+ cells at day 6 did not show significant differences. c Representative western blot showing activation of SMAD pathways upon BMP4, Activin A,
or TGFβ1 stimulation in WT and FOP iECs. d Western blot quantification of p-SMAD2 and p-SMAD1/5/8. Phosphorylation of SMAD2 was significantly
increased in WT and FOP iECs treated with TGFβ1 compared to untreated cells. p-SMAD2 and p-SMAD1/5/8 protein expression were normalized to
GAPDH protein expression. At least three separate experiments were run for WT and FOP iECs for each group. Error bars represent the mean ± one
standard deviation. Mean values were statistically different by Student’s t test: * p < 0.05, ** p < 0.01, *** p<0.005
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BMPRII expression levels were significantly lower in both
WT and FOP hiPSCs in comparison to the other two cell
types. Thus these differences in type II receptor expression
between cell types, independent of the presence of the
ACVR1 R206H allele, may account for the differences
found in SMAD signaling in ECs compared to hiPSCs.
Discussion
Aberrant BMP signaling can be found in many con-
ditions of heterotopic ossification, including vascular
calcification [31], atherosclerosis [32], and heterotopic
ossification [33]. However, further delineation of the
mechanisms inducing the abnormal bone formation has
been limited by the broad expression patterns of the
BMP ligands, potential differences in cell function
between rodent models and humans, and the diversity of
triggers that can incite heterotopic ossification. Genetic
models using hiPSCs allows us to create human cell line-
ages with endogenous levels of gene expression for de-
tailed studies.
Here, we used iECs to determine how ECs may con-
tribute to heterotopic bone formation as a result of
ACVR1 R206H expression. We show that iECs derived
from FOP hiPSCs, which express physiological levels of
the R206H ACVR1 activating mutation, are useful tools
for dissecting the cellular and molecular mechanisms
that cause this debilitating disease. In addition, our study
shows that the ACVR1 receptor may play a key role in
regulating EC commitment, and that the ACVR1 R206H
mutation may underlie the pathogenesis of abnormal
bone formation by changing the propensity of ECs to
undergo EndMT, possibly through variations in the cell’s
Fig. 5 Cell type-specific expression of SMADs and type I and II receptors. a Expression of the inhibitory SMAD6 and SMAD7 was higher in human
induced pluripotent stem cell (hiPSC)-derived endothelial cells (iECs) than in hiPSCs. Also, SMAD6 had significantly higher expression in fibrodysplasia
ossificans progressiva (FOP) iECs. b Activin A gene expression levels were higher in iECs than in hiPSCs; however, there was no difference in Activin A
levels between FOP and wild type (WT) by quantitative PCR or ELISA. c Gene expression analysis of WT ACVR1, ACVR1 R206H, and the ratio of R206H/
WT ACVR1. WT ACVR1 expression was higher in iECs compared to hiPSCs. WT ACVR1 levels were lower in FOP cells and ACVR1 R206H was detected only
in FOP cells, as expected. d ACVR2A, ACVR2B, and BMPRII gene expression analysis of WT and FOP hiPSCs, iECs, and iECs cultured in osteogenic media
(OB iEC). Type II receptor expression was differentially expressed based on cell type but not on ACVR1 R206H status. WT and FOP hiPSCs, iECs, and iECs
cultured in osteogenic media were run in at least three separate experiments for each group. Error bars represent the mean ± one standard deviation.
Mean values were statistically different by Student’s t test: * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.0001
Barruet et al. Stem Cell Research & Therapy  (2016) 7:115 Page 9 of 13
responses to different ligands for ACVR1 (Fig. 6). We
also show that ECs carrying the ACVR1 R206H receptor
produce increased amounts of collagen proteins, likely
contributing to the tissue fibrosis characteristic of het-
erotopic bone lesions.
Several studies suggest that multiple cell types, in-
cluding ECs [9], mesenchymal progenitors [22], peri-
cytes [20, 34], Tie2 cells [35, 36], and MSCs [37],
may contribute to heterotopic ossification. Unlike a
prior report [20], our detailed analysis revealed no
evidence for impaired endothelial formation from
FOP hiPSCs. In contrast, we found that FOP iECs
could form in conditions not normally permissive for
WT cells and that FOP iECs could express genes that
may predispose them towards EndMT. Although our
iEC model does not fully recapitulate the previously
reported findings of increased mature osteogenesis by
EC lineages in mice [9], our current in vitro condi-
tions may not be optimized for creating mature
mineral-depositing osteoblasts and thus limits our
ability to understand how ACVR1 signaling affects
the later steps of human osteogenesis. We also found
an increase of ECs in FOP hiPSCs cultured in osteo-
genic media, suggesting that FOP ECs may not dir-
ectly contribute to increased bone formation by
transdifferentiation into osteoblasts but rather by
acting as a supporting cell that helps establish a
bone-forming niche for a bona fide osteogenic pre-
cursor. This possibility is supported by the signifi-
cantly increased levels of collagen production found
in FOP iECs. Furthermore, we were unable to create
in vivo osteogenic implants made purely from the
iECs (not shown), suggesting that a more complex
cellular model may be needed. Addressing these im-
portant challenges is critical for future studies using
in vitro directed differentiation approaches to study
bone formation.
While our study cannot exclude roles for MSCs [22, 38]
or pericytes [20] in FOP, PECAM+/KDR+ EC precursors
could still be a potential cell source of osteoprogenitors.
Our observed increase in some mesenchymal, chondro-
genic, and osteogenic gene expression in FOP iECs sug-
gests that ACVR1 R206H can induce changes associated
with cell fate. Cell lineage identity is necessary for
homeostasis of most adult tissue and even subtle shifts
in cell identity can severely impact tissues as they
undergo regeneration after stress or injury. This loss of
lineage determination, combined with the increased
ability to make EC precursors in conditions not nor-
mally permissive in WT cells, may be critical early steps
for developing heterotopic ossification in FOP. Indeed,
a recent study has shown that increased cell plasticity
Fig. 6 Summary of using human induced pluripotent stem cell (hiPSCs) to understand fibrodysplasia ossificans progressiva (FOP) R206H ACVR1
effects on human endothelial cell (EC) lineages. FOP hiPSCs are able to differentiate into ECs in a non-permissive condition and show increased
osteogenic potential [14], which may reflect the increased number of ECs found in FOP lesions. FOP hiPSC-derived ECs (iECs) show increased
expression of mesenchymal, extracellular matrix, chondrogenic, and osteogenic markers, which may play a major role in the tissue fibrosis found
in patients with FOP during early stages of heterotopic ossification. FOP iECs show increased SMAD6 gene expression and respond differently to
different ligands such as BMP, which could be proposed as a mechanism for their loss of cellular commitment and their proficiency in undergoing
endothelial-to-mesenchymal transition
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can increase fibrogenesis in skeletal muscle, thus
impairing normal tissue regeneration [39]. Our data that
FOP iECs produce more extracellular matrix proteins
provide supporting evidence that this may be happening
in the early heterotopic ossification lesion, particularly
given that fibrosis is a key early feature in FOP [40] and
that changes in material properties can affect cell fate
[41, 42]. We would speculate that the formation of fi-
brosis contributes to changes in cell fate [41, 42] and ab-
normal tissue regeneration in FOP via increased cell
plasticity in skeletal muscle [39].
The recent identification of aberrant Activin A sig-
naling by ACVR1 R206H [11, 38] using transgene ex-
pression models suggested that Activin A could be
anti-angiogenic [43] and activated osteoblast differenti-
ation and extracellular matrix mineralization [44]. Our
results do not exclude FOP ECs as responders to Acti-
vin A, but indicate that FOP ECs do not contribute sig-
nificantly to Activin A production. However, we found
that FOP iECs responded differently from WT iECs
when stimulated with BMP4 but not with Activin A or
TGFβ1. We also saw an unexpected increase in
SMAD1/5/8 signaling when WT hiPSCs were stimu-
lated with Activin A. This is likely due to the different
mRNA levels of SMAD6 and SMAD7 seen in hiPSCs
versus ECs, as well as increased expression of ACVR1
and BMPRII and decreased levels of ACVR2A and
ACVR2B [45] in iECs versus hiPSCs. Surprisingly, we
also found that BMP4 treatment of WT iECs increased
SMAD2 phosphorylation. This could suggest that, des-
pite BMP4’s low binding affinity to type II receptors
[46], BMP4 may still be able to induce SMAD2 signal-
ing in the absence of a high-affinity ligand such as Acti-
vin A. Indeed, a few studies have reported that BMPs
could activate noncanonical SMAD2 [25, 26]. These
findings suggest that individual cell types may respond
differently to each ligand stimulus [47] and that spe-
cific clinical features of FOP may be caused by tissue-
specific expression of either receptors or ligands.
Conclusions
Together, our results show that EC lineages may con-
tribute to heterotopic bone formation in FOP by priming
an injury site with increased EC formation and changes
in extracellular matrix production and fibrosis. In
addition, BMPs and Activin A have a more complex
interaction than previously thought, and differences in
signaling via the type II receptors needs to be studied
further in abnormal bone formation, tissue fibrosis, or
the abnormal injury response in the pathogenesis of het-
erotopic bone formation. The broad expression of BMP
and Activin A, particularly after injury, suggests that
these mechanisms may be more generally applicable to
non-genetic forms of heterotopic ossification [48] and
potentially identify a new role for endothelial lineage
cells in both normal and pathogenic osteogenesis.
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